A subscription to JoVE is required to view this content. Sign in or start your free trial.
The protocol describes how to generate knock-out myoblasts using CRISPR/Cas9, starting from the design of guide-RNAs to the cellular cloning and characterization of the knock-out clones.
One important application of clustered regulatory interspaced short palindromic repeats (CRISPR)/Cas 9 is the development of knock-out cell lines, specifically to study the function of new genes/proteins associated with a disease, identified during the genetic diagnosis. For the development of such cell lines, two major issues have to be untangled: insertion of the CRISPR tools (the Cas9 and the guide RNA) with high efficiency into the chosen cells, and restriction of the Cas9 activity to the specific deletion of the chosen gene. The protocol described here is dedicated to the insertion of the CRISPR tools in difficult to transfect cells, such as muscle cells. This protocol is based on the use of lentiviruses, produced with plasmids publicly available, for which all the cloning steps are described to target a gene of interest. The control of Cas9 activity has been performed using an adaptation of a previously described system called KamiCas9, in which the transduction of the cells with a lentivirus encoding a guide RNA targeting the Cas9 allows the progressive abolition of Cas9 expression. This protocol has been applied to the development of a RYR1-knock out human muscle cell line, which has been further characterized at the protein and functional level, to confirm the knockout of this important calcium channel involved in muscle intracellular calcium release and in excitation-contraction coupling. The procedure described here can easily be applied to other genes in muscle cells or in other difficult to transfect cells and produce valuable tools to study these genes in human cells.
With the progress of gene sequencing and the identification of mutations in genes of unknown functions in a specific tissue, the development of relevant cellular models to understand the function of a new target gene and confirm its involvement in the related pathophysiological mechanisms constitutes an essential tool. In addition, these models are of major importance for future therapeutic developments1,2, and constitute an interesting alternative to the development of knock-out animal models in straight line with the international recommendations for reduction in the use of animals in experimentation. Gene e....
Muscle biopsies were obtained from the Bank of Tissues for Research (Myobank, a partner in the EU network EuroBioBank, Paris, France) in accordance with European recommendations and French legislation. Written informed consent was obtained from all individuals. Immortalized myoblasts were kindly produced by Dr. V. Mouly (Myology Institute, Paris, France), and the protocols were approved by Myology Institute ethic committee (MESRI, n AC-2019-3502).
1. CRISPR guide design
This protocol was applied to immortalized myoblasts from a healthy subject15 (so-called HM cells, for human myoblasts), in which the RyR1 has been previously characterized16, in order to knock out the RYR1 gene encoding the RyR1 protein. The design of the guides RNA was made to delete the sequence encompassing part of exon 101 and intron 101 of the gene. Deletion of part of exon 101 is foreseen to result in disruption of the reading frame. In addition, exon 101 enc.......
A major step on the way to the characterization of genes of unknown function involved in pathologies is the development of relevant cellular models to study the function of these genes. The use of gene editing using CRISPR/Cas9 is an exponentially growing field of research, and the development of knock-out models as presented here is among its most widely used applications. In this context, we propose here a versatile protocol to develop a human cell line knock-out in any gene of interest, allowing the characterization o.......
This work was funded by grants from Association Française contre les myopathies (AFM-Téléthon) and from Auvergne-Rhône Alpes Région (AURA).
....Name | Company | Catalog Number | Comments |
Anti-CACNA1S antibody | Sigma-Aldrich | HPA048892 | Primary antibody |
Blp I | NE BioLabs | R0585S | Restriction enzyme |
CalPhos Mammalian Transfection Kit | Takara | 631312Â | Transfection kit |
Easy blot anti Mouse IgG | GeneTex | GTX221667-01 | HRP secondary antibody |
Easy blot anti Rabbit IgG | GeneTex | GTX221666 | HRP secondary antibody |
Fluo-4 direct | Molecular Probes | F10472 | Calcium imaging |
GAPDH(14C10) Rabbit mAb | Cell Signaling Technology | #2118 | Primary antibody |
HindIII | Fermentas | ER0501 | Restriction enzyme |
InFusion HD Precision Plus | Takara | 638920 | Ligation kit |
MasterMix Phusion High Fidelity with GC | ThermoFisher Scientific | F532L | Mix for PCR reaction with High fidelity Taq polymerase and dNTPs |
Myosin Heavy Chain antibody | DHSB | MF20 | Primary antibody |
NucleoBond Xtra Maxi EF | Macherey-Nagel | REFÂ 740424 | Maxipreparation kit for purification of plasmids |
NucleoSpin Gel and PCR Clean-up | Macherey-Nagel | 740609 | DNA purification |
NucleoSpin Tissue | Macherey-Nagel | 740952 | Kit for DNA extraction from cell |
One Shot Stbl3 Chemically Competent E. coli | ThermoFisher Scientific | C737303 | Chemically competent cells |
Plasmid #87904 | Addgene | 87904 | Lentiviral plasmid encoding the SpCas9 (for LV-Cas9) |
Plasmid #87919 | Addgene | 87919 | Lentiviral backbone for insertion of cassette with guides (for LV-guide-target) |
Plasmid #12260 | Addgene | 12260 | Lentiviral plasmid encoding lentiviral packaging GAG POL |
Plasmid #8454 | Addgene | 8454 | Lentiviral plasmid encoding envelope protein for producing lentiviral and MuLV retroviral particles |
V5 Tag Monoclonal Antibody | Invitrogene | R96025Â | Primary antibody |
XL10-Gold Ultracompetent Cells | Agilent | 200317 | Chemically competent cells |
Xma I | NE BioLabs | R0180S | Restriction enzyme |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved